Identification of progressors in osteoarthritis by combining biochemical and MRI based markers.

TY - JOUR

T1 - Identification of progressors in osteoarthritis by combining biochemical and MRI based markers.

AU - Dam, Erik Bjørnager

AU - Loog, Marco

AU - Christiansen, Claus

AU - Byrjalsen, Inger

AU - Folkesson, Jenny Maria

AU - Nielsen, Mads

AU - Qazi, Arish Asif

AU - Pettersen, Paola

AU - Garnero, Patrick

AU - Karsdal, Morten A

PY - 2009/7/24

Y1 - 2009/7/24

N2 - At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations of biochemical and magnetic resonance imaging (MRI)-based markers provided effective diagnostic and prognostic tools for identifying subjects with high risk of progression. Specifically, we investigated aggregate cartilage longevity markers combining markers of breakdown, quantity, and quality.

AB - At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations of biochemical and magnetic resonance imaging (MRI)-based markers provided effective diagnostic and prognostic tools for identifying subjects with high risk of progression. Specifically, we investigated aggregate cartilage longevity markers combining markers of breakdown, quantity, and quality.

U2 - 10.1186/ar2774

DO - 10.1186/ar2774

M3 - Journal article

C2 - 19630944

SN - 1478-6362

VL - 11

SP - 1

EP - 11

JO - Arthritis Research & Therapy

JF - Arthritis Research & Therapy

IS - 4

ER -